William Martin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
William Martin has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Silvia Nelli
Integrative & Systems Biology, Faculty of Biomedical & Life Sciences, West Medical Building, University of Glasgow, Glasgow, G12 8QQ, Scotland, UK
9 shared publicationsWilliam S Wilson
Division of Neuroscience & Biomedical Systems, Institute of Biomedical & Life Sciences, West Medical Building, University of Glasgow, Glasgow G12 8QQ, Scotland
6 shared publications- Alister James McNeish
Reading School of Pharmacy, School of Chemistry, Food and Pharmacy, University of Reading, Reading, UK
3 shared publications Alison Stirrat
Division of Neuroscience and Biomedical Systems, Institute of Biomedical and Life Sciences, West Medical Building, University of Glasgow, Glasgow G12 8QQ, Scotland, UK
2 shared publicationsFiona J Dowell
22Institute of Comparative Medicine, University of Glasgow Veterinary School, Bearsden Road, Glasgow, G61 1QH, Scotland
2 shared publicationsJohn Craig
Integrative & Systems Biology, Faculty of Biomedical & Life Sciences, University of Glasgow, Glasgow, UK
2 shared publications
Latest Publications
- Open Access
- 25 June 2010
- Published by Wiley in British Journal of Pharmacology
- Vol. 160 (6) , 1476-1483
Differential sensitivity of basal and acetylcholine‐induced activity of nitric oxide to blockade by asymmetric dimethylarginine in the rat aorta
Background and purpose: Previous work has shown that NG‐monomethyl‐l‐arginine (l‐NMMA) paradoxically inhibits basal, but not ACh‐stimulated activity of nitric oxide in rat aorta. The aim of this study was to determine if the endogenously produced agent, asymmetric NG, NG‐dimethyl‐l‐arginine (ADMA), also exhibits this unusual selective blocking action.Experimental approach: The effect of ADMA on basal nitric oxide activity was assessed by examining its ability to enhance phenylephrine (PE)‐induced tone in endothelium‐containing rings. Its effect on ACh‐induced relaxation was assessed both in conditions where ADMA greatly enhanced PE tone and where tone was carefully matched with control tissues at a range of different levels.Key results: ADMA (100 µM) potentiated PE‐induced contraction, consistent with inhibition of basal nitric oxide activity. Higher concentrations (300–1000 µM) had no greater effect. Although ADMA (100 µM) also appeared to block ACh‐induced relaxation when it enhanced PE tone to maximal levels, virtually no block was seen at intermediate levels of tone in the presence of ADMA. Even ADMA at 1000 µM had no effect on the maximal relaxation to ACh, although it produced a small (two‐ to threefold) reduction in sensitivity. ADMA andl‐NMMA, likel‐arginine (all at 1000 µM), protected ACh‐induced relaxation against blockade byl‐NAME (30 µM).Conclusions and implications: In the rat aorta, ADMA, likel‐NMMA, blocks basal activity of nitric oxide, but has little effect on that stimulated by ACh. Further studies are required to explain these seemingly anomalous actions of ADMA andl‐NMMA.
- 25 June 2010
- Published by Wiley in British Journal of Pharmacology
- Vol. 160 (6) , 1476-1483
Open AccessDifferential sensitivity of basal and acetylcholine‐induced activity of nitric oxide to blockade by asymmetric dimethylarginine in the rat aorta
Background and purpose: Previous work has shown that NG‐monomethyl‐l‐arginine (l‐NMMA) paradoxically inhibits basal, but not ACh‐stimulated activity of nitric oxide in rat aorta. The aim of this study was to determine if the endogenously produced agent, asymmetric NG, NG‐dimethyl‐l‐arginine (ADMA), also exhibits this unusual selective blocking action.Experimental approach: The effect of ADMA on basal nitric oxide activity was assessed by examining its ability to enhance phenylephrine (PE)‐induced tone in endothelium‐containing rings. Its effect on ACh‐induced relaxation was assessed both in conditions where ADMA greatly enhanced PE tone and where tone was carefully matched with control tissues at a range of different levels.Key results: ADMA (100 µM) potentiated PE‐induced contraction, consistent with inhibition of basal nitric oxide activity. Higher concentrations (300–1000 µM) had no greater effect. Although ADMA (100 µM) also appeared to block ACh‐induced relaxation when it enhanced PE tone to maximal levels, virtually no block was seen at intermediate levels of tone in the presence of ADMA. Even ADMA at 1000 µM had no effect on the maximal relaxation to ACh, although it produced a small (two‐ to threefold) reduction in sensitivity. ADMA andl‐NMMA, likel‐arginine (all at 1000 µM), protected ACh‐induced relaxation against blockade byl‐NAME (30 µM).Conclusions and implications: In the rat aorta, ADMA, likel‐NMMA, blocks basal activity of nitric oxide, but has little effect on that stimulated by ACh. Further studies are required to explain these seemingly anomalous actions of ADMA andl‐NMMA.
- Open Access
- 1 July 2009
- Published by Elsevier in European Journal of Pharmacology
- Vol. 614 (1-3) , 206-211
Oxidation by trace Cu2+ ions underlies the ability of ascorbate to induce vascular dysfunction in the rat perfused mesentery
- 1 July 2009
- Published by Elsevier in European Journal of Pharmacology
- Vol. 614 (1-3) , 206-211
Open AccessOxidation by trace Cu2+ ions underlies the ability of ascorbate to induce vascular dysfunction in the rat perfused mesentery
- Open Access
- 3 June 2009
- Published by Wiley in British Journal of Pharmacology
- Vol. 157 (4) , 537-539
Nitroxyl anion – the universal signalling partner of endogenously produced nitric oxide?
Although it is generally assumed that the primary product of the three isoforms of NO synthase is the nitric oxide radical (NO•), growing evidence suggests that the one‐electron reduced form of nitrogen monoxide, nitroxyl anion (NO‐), may be a natural co‐product. Thus, evidence from conduit and resistance arteries and nitrergically innervated tissues indicates that NO‐ exerts widespread signalling functions alongside NO• in the cardiovascular and autonomic nervous systems, and perhaps beyond. In this issue of the BJP Andrews et al. add to this debate by providing strong evidence that NO• and HNO both contribute to the EDRF‐mediated component of in mouse (MMA) and rat (RMA) mesenteric resistance arteries. British Journal of Pharmacology (2009) 157, 537–539; doi:10.1111/j.1476‐5381.2009.00153.xThis article is a commentary on Andrews et al., pp. 540–550 of this issue and is part of a themed section on Endothelium in Pharmacology. For a list of all articles in this section see the end of this paper, or visit: http://www3.interscience.wiley.com/journal/121548564/issueyear?year=2009
- 3 June 2009
- Published by Wiley in British Journal of Pharmacology
- Vol. 157 (4) , 537-539
Open AccessNitroxyl anion – the universal signalling partner of endogenously produced nitric oxide?
Although it is generally assumed that the primary product of the three isoforms of NO synthase is the nitric oxide radical (NO•), growing evidence suggests that the one‐electron reduced form of nitrogen monoxide, nitroxyl anion (NO‐), may be a natural co‐product. Thus, evidence from conduit and resistance arteries and nitrergically innervated tissues indicates that NO‐ exerts widespread signalling functions alongside NO• in the cardiovascular and autonomic nervous systems, and perhaps beyond. In this issue of the BJP Andrews et al. add to this debate by providing strong evidence that NO• and HNO both contribute to the EDRF‐mediated component of in mouse (MMA) and rat (RMA) mesenteric resistance arteries. British Journal of Pharmacology (2009) 157, 537–539; doi:10.1111/j.1476‐5381.2009.00153.xThis article is a commentary on Andrews et al., pp. 540–550 of this issue and is part of a themed section on Endothelium in Pharmacology. For a list of all articles in this section see the end of this paper, or visit: http://www3.interscience.wiley.com/journal/121548564/issueyear?year=2009
- Open Access
- 1 March 2008
- Published by Wiley in British Journal of Pharmacology
- Vol. 153 (6) , 1162-1168
Flow‐induced enhancement of vasoconstriction and blockade of endothelium‐derived hyperpolarizing factor (EDHF) by ascorbate in the rat mesentery
Background and purpose: We previously reported that ascorbate inhibits flow‐ and agonist‐induced, EDHF‐mediated vasodilatation in the bovine ciliary circulation. This study examined whether ascorbate had similar actions in the rat mesenteric vasculature.Experimental approach: The effects of ascorbate were examined both in rat second order mesenteric arterial rings suspended in a static wire myograph and the rat mesentery perfused at different rates of flow.Key results: Ascorbate (50 μM) had no effect on U46619‐induced tone or acetylcholine‐induced, EDHF‐mediated vasodilatation in either rings of mesenteric artery or the perfused mesentery at rates of flow below 10 ml min−1. At higher rates of flow, ascorbate produced two distinct effects in the rat mesentery: a rapid and maintained enhancement of vasoconstrictor tone and a slow (max at 3 h) inhibition of acetylcholine‐induced, EDHF‐mediated vasodilatation. The enhancement of vasoconstrictor tone appeared to be due to inhibition of flow‐induced EDHF‐like activity, since it was endothelium‐dependent, but could be elicited during blockade of nitric oxide synthase and cyclooxygenase. Despite this, the classical inhibitors of EDHF, apamin and charybdotoxin, failed to affect the ascorbate‐induced enhancement of tone, although they inhibited acetylcholine‐induced vasodilatation.Conclusions and implications: Ascorbate inhibits both flow‐ and agonist‐induced EDHF in the rat mesentery. The strikingly different timecourses of these two effects, together with their differential sensitivity to apamin and charybdotoxin, suggest that the flow‐ and agonist‐induced EDHFs in the rat mesenteric vasculature may either be different entities or operate by different mechanisms.British Journal of Pharmacology (2008) 153, 1162–1168; doi:10.1038/sj.bjp.0707499; published online 8 October 2007
- 1 March 2008
- Published by Wiley in British Journal of Pharmacology
- Vol. 153 (6) , 1162-1168
Open AccessFlow‐induced enhancement of vasoconstriction and blockade of endothelium‐derived hyperpolarizing factor (EDHF) by ascorbate in the rat mesentery
Background and purpose: We previously reported that ascorbate inhibits flow‐ and agonist‐induced, EDHF‐mediated vasodilatation in the bovine ciliary circulation. This study examined whether ascorbate had similar actions in the rat mesenteric vasculature.Experimental approach: The effects of ascorbate were examined both in rat second order mesenteric arterial rings suspended in a static wire myograph and the rat mesentery perfused at different rates of flow.Key results: Ascorbate (50 μM) had no effect on U46619‐induced tone or acetylcholine‐induced, EDHF‐mediated vasodilatation in either rings of mesenteric artery or the perfused mesentery at rates of flow below 10 ml min−1. At higher rates of flow, ascorbate produced two distinct effects in the rat mesentery: a rapid and maintained enhancement of vasoconstrictor tone and a slow (max at 3 h) inhibition of acetylcholine‐induced, EDHF‐mediated vasodilatation. The enhancement of vasoconstrictor tone appeared to be due to inhibition of flow‐induced EDHF‐like activity, since it was endothelium‐dependent, but could be elicited during blockade of nitric oxide synthase and cyclooxygenase. Despite this, the classical inhibitors of EDHF, apamin and charybdotoxin, failed to affect the ascorbate‐induced enhancement of tone, although they inhibited acetylcholine‐induced vasodilatation.Conclusions and implications: Ascorbate inhibits both flow‐ and agonist‐induced EDHF in the rat mesentery. The strikingly different timecourses of these two effects, together with their differential sensitivity to apamin and charybdotoxin, suggest that the flow‐ and agonist‐induced EDHFs in the rat mesenteric vasculature may either be different entities or operate by different mechanisms.British Journal of Pharmacology (2008) 153, 1162–1168; doi:10.1038/sj.bjp.0707499; published online 8 October 2007
- Open Access
- 1 February 2007
- Published by Wiley in British Journal of Pharmacology
- Vol. 150 (4) , 488-493
Differential effects of nitric oxide synthase inhibitors on endothelium‐dependent and nitrergic nerve‐mediated vasodilatation in the bovine ciliary artery
Background and purpose: We have previously demonstrated that L‐NMMA (NG‐monomethyl‐L‐arginine) selectively inhibits vasodilatation produced by endothelium‐derived nitric oxide but not nitrergic nerves in the bovine penile artery. The present study investigated whether L‐NMMA had a similar selective action in the bovine ciliary artery. We also investigated whether two recently introduced inhibitors of neuronal nitric oxide synthase (nNOS), AAAN (N‐(4S)‐4‐amino‐5‐[aminoethyl]aminopentyl‐N′‐nitroguanidine) and L‐NPA (NG‐propyl‐L‐arginine), produced selective blockade of vasodilatation induced by nitrergic nerves but not endothelium‐derived nitric oxide. Experimental approach: Rings of bovine ciliary artery were suspended in a wire myograph for tension recording. Neurogenic (nitrergic) vasodilatation was elicited by electrical field stimulation, and endothelium‐dependent, nitric oxide‐mediated dilatation was evoked using bradykinin. Key results: L‐NMMA inhibited vasodilatation induced by endothelium‐derived nitric oxide but not the nitrergic nerves. In fact, L‐NMMA, acted like L‐arginine in protecting nitrergic vasodilatation against inhibition by L‐NAME (NG‐nitro‐L‐arginine methyl ester). AAAN had no effect on vasodilatation induced by either nitrergic nerves or endothelium‐derived nitric oxide, but L‐NPA inhibited both with equal potency. Conclusions and implications: In the bovine ciliary artery, L‐NMMA acts as a selective inhibitor of the vasodilatation induced via endothelial NOS, without affecting that operating via nNOS. Furthermore, the putative nNOS inhibitors, AAAN and L‐NPA failed to produce the expected selective inhibition of nitrergic vasodilatation in this artery. British Journal of Pharmacology (2007) 150, 488–493. doi:10.1038/sj.bjp.0707113
- 1 February 2007
- Published by Wiley in British Journal of Pharmacology
- Vol. 150 (4) , 488-493
Open AccessDifferential effects of nitric oxide synthase inhibitors on endothelium‐dependent and nitrergic nerve‐mediated vasodilatation in the bovine ciliary artery
Background and purpose: We have previously demonstrated that L‐NMMA (NG‐monomethyl‐L‐arginine) selectively inhibits vasodilatation produced by endothelium‐derived nitric oxide but not nitrergic nerves in the bovine penile artery. The present study investigated whether L‐NMMA had a similar selective action in the bovine ciliary artery. We also investigated whether two recently introduced inhibitors of neuronal nitric oxide synthase (nNOS), AAAN (N‐(4S)‐4‐amino‐5‐[aminoethyl]aminopentyl‐N′‐nitroguanidine) and L‐NPA (NG‐propyl‐L‐arginine), produced selective blockade of vasodilatation induced by nitrergic nerves but not endothelium‐derived nitric oxide. Experimental approach: Rings of bovine ciliary artery were suspended in a wire myograph for tension recording. Neurogenic (nitrergic) vasodilatation was elicited by electrical field stimulation, and endothelium‐dependent, nitric oxide‐mediated dilatation was evoked using bradykinin. Key results: L‐NMMA inhibited vasodilatation induced by endothelium‐derived nitric oxide but not the nitrergic nerves. In fact, L‐NMMA, acted like L‐arginine in protecting nitrergic vasodilatation against inhibition by L‐NAME (NG‐nitro‐L‐arginine methyl ester). AAAN had no effect on vasodilatation induced by either nitrergic nerves or endothelium‐derived nitric oxide, but L‐NPA inhibited both with equal potency. Conclusions and implications: In the bovine ciliary artery, L‐NMMA acts as a selective inhibitor of the vasodilatation induced via endothelial NOS, without affecting that operating via nNOS. Furthermore, the putative nNOS inhibitors, AAAN and L‐NPA failed to produce the expected selective inhibition of nitrergic vasodilatation in this artery. British Journal of Pharmacology (2007) 150, 488–493. doi:10.1038/sj.bjp.0707113
- 28 February 2006
- Published by Elsevier in European Journal of Pharmacology
- Vol. 534 (1-3) , 152-158
Ascorbate elevates perfusion pressure in the bovine extraocular long posterior ciliary artery: Role of endothelium-derived hyperpolarizing factor (EDHF)
- 28 February 2006
- Published by Elsevier in European Journal of Pharmacology
- Vol. 534 (1-3) , 152-158
Ascorbate elevates perfusion pressure in the bovine extraocular long posterior ciliary artery: Role of endothelium-derived hyperpolarizing factor (EDHF)
- Open Access
- 1 August 2005
- Published by Wiley in British Journal of Pharmacology
- Vol. 145 (7) , 1001-1008
Biphasic neurogenic vasodilatation in the bovine intraocular long posterior ciliary artery: involvement of nitric oxide and an additional unidentified neurotransmitter
- 1 August 2005
- Published by Wiley in British Journal of Pharmacology
- Vol. 145 (7) , 1001-1008
Open AccessBiphasic neurogenic vasodilatation in the bovine intraocular long posterior ciliary artery: involvement of nitric oxide and an additional unidentified neurotransmitter
- Open Access
- 1 August 2004
- Published by Wiley in British Journal of Pharmacology
- Vol. 142 (7) , 1081-1090
Requirement for flow in the blockade of endothelium-derived hyperpolarizing factor (EDHF) by ascorbate in the bovine ciliary artery
- 1 August 2004
- Published by Wiley in British Journal of Pharmacology
- Vol. 142 (7) , 1081-1090
Open AccessRequirement for flow in the blockade of endothelium-derived hyperpolarizing factor (EDHF) by ascorbate in the bovine ciliary artery
- Open Access
- 1 July 2003
- Published by Wiley in British Journal of Pharmacology
- Vol. 139 (5) , 982-988
Evaluation of potassium ion as the endothelium‐derived hyperpolarizing factor (EDHF) in the bovine coronary artery
This study explored the role of the potassium ion in endothelium‐derived hyperpolarizing factor (EDHF)‐mediated vasodilatation in the bovine coronary artery. Bradykinin‐induced, EDHF‐mediated vasodilatation was blocked by the Na+–K+ ATPase inhibitor, ouabain (1 μM), in a time‐dependent manner, with maximal blockade seen after 90 min. In contrast, the KIR channel inhibitor, Ba2+ (30 μM), had no effect. When the potassium content of the bathing solution was increased in a single step from 5.9 to 7–19 mM, powerful vasodilatation (max. 75.9±3.6%) was observed. Vasodilatation was transient and, consequently, cumulative addition of potassium produced little vasodilatation, with vasoconstriction predominating at the higher concentrations. The magnitude of potassium‐induced vasodilatation was similar in endothelium‐containing and endothelium‐denuded rings, and was unaffected by Ba2+ (30 μM), but abolished by ouabain (1 μM). Ouabain (1 μM, 90 min) powerfully blocked bradykinin‐induced, nitric oxide‐mediated vasodilatation as well as that induced by the nitrovasodilator, glyceryl trinitrate, but that induced by the KATP channel opener, levcromakalim, was hardly affected. Thus, activation of Na+–K+ ATPase is likely to be involved in the vasodilator responses of the bovine coronary artery to both nitric oxide and EDHF. These findings, together with the ability of potassium to induce powerful, ouabain‐ but not Ba2+‐sensitive, endothelium‐independent vasodilatation, are consistent with this ion contributing to the EDHF response in this tissue. British Journal of Pharmacology (2003) 139, 982–988. doi:10.1038/sj.bjp.0705329
- 1 July 2003
- Published by Wiley in British Journal of Pharmacology
- Vol. 139 (5) , 982-988
Open AccessEvaluation of potassium ion as the endothelium‐derived hyperpolarizing factor (EDHF) in the bovine coronary artery
This study explored the role of the potassium ion in endothelium‐derived hyperpolarizing factor (EDHF)‐mediated vasodilatation in the bovine coronary artery. Bradykinin‐induced, EDHF‐mediated vasodilatation was blocked by the Na+–K+ ATPase inhibitor, ouabain (1 μM), in a time‐dependent manner, with maximal blockade seen after 90 min. In contrast, the KIR channel inhibitor, Ba2+ (30 μM), had no effect. When the potassium content of the bathing solution was increased in a single step from 5.9 to 7–19 mM, powerful vasodilatation (max. 75.9±3.6%) was observed. Vasodilatation was transient and, consequently, cumulative addition of potassium produced little vasodilatation, with vasoconstriction predominating at the higher concentrations. The magnitude of potassium‐induced vasodilatation was similar in endothelium‐containing and endothelium‐denuded rings, and was unaffected by Ba2+ (30 μM), but abolished by ouabain (1 μM). Ouabain (1 μM, 90 min) powerfully blocked bradykinin‐induced, nitric oxide‐mediated vasodilatation as well as that induced by the nitrovasodilator, glyceryl trinitrate, but that induced by the KATP channel opener, levcromakalim, was hardly affected. Thus, activation of Na+–K+ ATPase is likely to be involved in the vasodilator responses of the bovine coronary artery to both nitric oxide and EDHF. These findings, together with the ability of potassium to induce powerful, ouabain‐ but not Ba2+‐sensitive, endothelium‐independent vasodilatation, are consistent with this ion contributing to the EDHF response in this tissue. British Journal of Pharmacology (2003) 139, 982–988. doi:10.1038/sj.bjp.0705329
- Open Access
- 1 March 2003
- Published by Wiley in British Journal of Pharmacology
- Vol. 138 (6) , 1172-1180
Differential effects of ascorbate on endothelium-derived hyperpolarizing factor (EDHF)-mediated vasodilatation in the bovine ciliary vascular bed and coronary artery
- 1 March 2003
- Published by Wiley in British Journal of Pharmacology
- Vol. 138 (6) , 1172-1180
Open AccessDifferential effects of ascorbate on endothelium-derived hyperpolarizing factor (EDHF)-mediated vasodilatation in the bovine ciliary vascular bed and coronary artery